Cadazolid

Drug Profile

Cadazolid

Alternative Names: ACT-179811

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Anti-infectives; Antibacterials; Carboxylic acids; Oxazolidinones; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Clostridium infections

Most Recent Events

  • 12 Apr 2017 Actelion Pharmaceuticals plans a phase II/III trial for Clostridium infections (In infants, In children, In adolescents) in USA, Belgium, Canada, Czech Republic, Hungary, Italy, Poland, Romania and Spain (PO, Suspension) (NCT03105479)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Clostridium-infections(In the elderly, In adults) in Croatia (PO, Suspension)
  • 02 Sep 2015 No recent reports on development identified - Phase-II for Clostridium infections in Sweden, United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top